Carcinogenesis Advance Access originally published online on August 3, 2006
Carcinogenesis 2007 28(1):130-135; doi:10.1093/carcin/bgl140
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Characterization of a preclinical model of simultaneous breast and ovarian cancer progression
1 Breast Cancer Prevention Center, University of Kansas Medical Center Kansas City, KS 66160, USA
2 Department of Molecular and Integrative Physiology, University of Kansas Medical Center Kansas City, KS 66160, USA
3 Department of Internal Medicine, University of Kansas Medical Center Kansas City, KS 66160, USA
4 Department of Radiation Oncology, University of Kansas Medical Center Kansas City, KS 66160, USA
5 Center for Reproductive Sciences, University of Kansas Medical Center Kansas City, KS 66160, USA
*To whom correspondence should be addressed. Email: bpetroff{at}kumc.edu
Women at increased risk for breast cancer are often also at increased risk for ovarian cancer, reflecting common risk factors and intertwined etiologies for both diseases. Unlike breast cancer prevention, primary ovarian cancer prevention has been impractical due to the low incidence, lack of risk and response biomarkers and difficulties in sampling ovarian tissue. Challenges in the development of ovarian cancer prevention drugs, however, may be circumvented through the development of breast cancer prevention strategies that simultaneously decrease ovarian cancer. In the present study, three commonly used mammary cancer carcinogen models [7,12-dimethylbenz[
]anthracene (DMBA), N-methyl-N-nitrosourea (MNU) and estradiol (E2)] were combined with local ovarian DMBA administration to induce progression to mammary and ovarian cancer concurrently in the rat. Animals were treated for 3 or 6 months, and tissue histology as well as proliferation, hormonal and inflammation biomarkers were assessed. Mammary and ovarian morphologies (measured as descriptive histology and dysplasia scores) were normal in vehicle controls. Mammary hyperplasia was observed in DMBA/DMBA (mammary carcinogen/ovarian carcinogen) and MNU/DMBA-treated rats; however, ovarian preneoplastic changes were seldom observed after these treatments. All E2/DMBA-treated rats had mammary hyperplasia, atypia, ductal carcinoma in situ and/or invasive adenocarcinoma, while 50% also developed preneoplastic changes in the ovary (ovarian epithelial and stromal hyperplasia and inclusion cyst formation). In both the mammary gland and ovary, decreased estrogen receptor alpha expression was detected, and in the mammary gland elevated Ki-67 and cyclooxygenase-2 expressions were observed. This combined breast and ovarian cancer rat model (systemic E2 treatment and local ovarian DMBA) may be useful for future dual target breast and ovarian cancer prevention studies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G Esendagli, G Yilmaz, H Canpinar, A Gunel-Ozcan, M O Guc, and D Guc Coexistence of different tissue tumourigenesis in an N-methyl-N-nitrosourea-induced mammary carcinoma model: a histopathological report in Sprague-Dawley rats Lab Anim, January 1, 2009; 43(1): 60 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Ting, B. F. Kimler, C. J. Fabian, and B. K. Petroff Tamoxifen Prevents Premalignant Changes of Breast, but not Ovarian, Cancer in Rats at High Risk for Both Diseases Cancer Prevention Research, December 1, 2008; 1(7): 546 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Murdoch, E. A. Van Kirk, and Youqing Shen Pathogenic Reactions of the Ovarian Surface Epithelium to Ovulation, Dimethylbenzanthracene, and Estrogen are Negated by Vitamin E Reproductive Sciences, October 1, 2008; 15(8): 839 - 845. [Abstract] [PDF]
|
|